abrdn World Healthcare Fund Q1 2025 Commentary
Source: SeekingAlpha
2025-06-03 08:20:00 ET
Summary
- The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter.
- The top three detractors over the quarter were Novo Nordisk, uniQure and Teva Pharmaceutical Industries.
- The top three positive contributors were Roche Holding, AbbVie and AstraZeneca.
Fund performance
Read the full article on Seeking Alpha
For further details see:
abrdn World Healthcare Fund Q1 2025 Commentary
Mereo BioPharma Group
NASDAQ: MREO
MREO Trading
-1.54% G/L:
$0.3962 Last:
896,793 Volume:
$0.3849 Open:
MREO Latest News
March 03, 2026 09:00:00 am
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo Lawsuit - MREO
February 24, 2026 09:00:00 am
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo BioPharma Group plc Lawsuit - MREO
MREO Stock Data
$64,633,660
109,222,507
1.45%
18
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
